Identification of biomarkers for apoptosis in cancer cell lines using metabolomics: Tools for individualized medicine

Anna Halama, N. Riesen, G. Möller, M. Hrabě de Angelis, J. Adamski

Research output: Contribution to journalReview article

40 Citations (Scopus)

Abstract

Background: Metabolomics is a versatile unbiased method to search for biomarkers of human disease. In particular, one approach in cancer therapy is to promote apoptosis in tumour cells; this could be improved with specific biomarkers of apoptosis for monitoring treatment. We recently observed specific metabolic patterns in apoptotic cell lines; however, in that study, apoptosis was only induced with one pro-apoptotic agent, staurosporine. Objective: The aim of this study was to find novel biomarkers of apoptosis by verifying our previous findings using two further pro-apoptotic agents, 5-fluorouracil and etoposide, that are commonly used in anticancer treatment. Methods: Metabolic parameters were assessed in HepG2 and HEK293 cells using the newborn screening assay adapted for cell culture approaches, quantifying the levels of amino acids and acylcarnitines with mass spectrometry. Results: We were able to identify apoptosis-specific changes in the metabolite profile. Moreover, the amino acids alanine and glutamate were both significantly up-regulated in apoptotic HepG2 and HEK293 cells irrespective of the apoptosis inducer. Conclusion: Our observations clearly indicate the potential of metabolomics in detecting metabolic biomarkers applicable in theranostics and for monitoring drug efficacy.

Original languageEnglish
Pages (from-to)425-439
Number of pages15
JournalJournal of Internal Medicine
Volume274
Issue number5
DOIs
Publication statusPublished - 1 Nov 2013
Externally publishedYes

Fingerprint

Precision Medicine
Metabolomics
Biomarkers
Apoptosis
Cell Line
Neoplasms
HEK293 Cells
Hep G2 Cells
Amino Acids
Staurosporine
Drug Monitoring
Etoposide
Fluorouracil
Alanine
Glutamic Acid
Mass Spectrometry
Therapeutics
Cell Culture Techniques

Keywords

  • Apoptosis
  • Biomarkers
  • Cancer
  • Mass spectrometry
  • Metabolomics

ASJC Scopus subject areas

  • Internal Medicine

Cite this

Identification of biomarkers for apoptosis in cancer cell lines using metabolomics : Tools for individualized medicine. / Halama, Anna; Riesen, N.; Möller, G.; Hrabě de Angelis, M.; Adamski, J.

In: Journal of Internal Medicine, Vol. 274, No. 5, 01.11.2013, p. 425-439.

Research output: Contribution to journalReview article

Halama, Anna ; Riesen, N. ; Möller, G. ; Hrabě de Angelis, M. ; Adamski, J. / Identification of biomarkers for apoptosis in cancer cell lines using metabolomics : Tools for individualized medicine. In: Journal of Internal Medicine. 2013 ; Vol. 274, No. 5. pp. 425-439.
@article{d71ed2a7e49749c5923cdd4e9958f228,
title = "Identification of biomarkers for apoptosis in cancer cell lines using metabolomics: Tools for individualized medicine",
abstract = "Background: Metabolomics is a versatile unbiased method to search for biomarkers of human disease. In particular, one approach in cancer therapy is to promote apoptosis in tumour cells; this could be improved with specific biomarkers of apoptosis for monitoring treatment. We recently observed specific metabolic patterns in apoptotic cell lines; however, in that study, apoptosis was only induced with one pro-apoptotic agent, staurosporine. Objective: The aim of this study was to find novel biomarkers of apoptosis by verifying our previous findings using two further pro-apoptotic agents, 5-fluorouracil and etoposide, that are commonly used in anticancer treatment. Methods: Metabolic parameters were assessed in HepG2 and HEK293 cells using the newborn screening assay adapted for cell culture approaches, quantifying the levels of amino acids and acylcarnitines with mass spectrometry. Results: We were able to identify apoptosis-specific changes in the metabolite profile. Moreover, the amino acids alanine and glutamate were both significantly up-regulated in apoptotic HepG2 and HEK293 cells irrespective of the apoptosis inducer. Conclusion: Our observations clearly indicate the potential of metabolomics in detecting metabolic biomarkers applicable in theranostics and for monitoring drug efficacy.",
keywords = "Apoptosis, Biomarkers, Cancer, Mass spectrometry, Metabolomics",
author = "Anna Halama and N. Riesen and G. M{\"o}ller and {Hrabě de Angelis}, M. and J. Adamski",
year = "2013",
month = "11",
day = "1",
doi = "10.1111/joim.12117",
language = "English",
volume = "274",
pages = "425--439",
journal = "Journal of Internal Medicine",
issn = "0954-6820",
publisher = "Wiley-Blackwell",
number = "5",

}

TY - JOUR

T1 - Identification of biomarkers for apoptosis in cancer cell lines using metabolomics

T2 - Tools for individualized medicine

AU - Halama, Anna

AU - Riesen, N.

AU - Möller, G.

AU - Hrabě de Angelis, M.

AU - Adamski, J.

PY - 2013/11/1

Y1 - 2013/11/1

N2 - Background: Metabolomics is a versatile unbiased method to search for biomarkers of human disease. In particular, one approach in cancer therapy is to promote apoptosis in tumour cells; this could be improved with specific biomarkers of apoptosis for monitoring treatment. We recently observed specific metabolic patterns in apoptotic cell lines; however, in that study, apoptosis was only induced with one pro-apoptotic agent, staurosporine. Objective: The aim of this study was to find novel biomarkers of apoptosis by verifying our previous findings using two further pro-apoptotic agents, 5-fluorouracil and etoposide, that are commonly used in anticancer treatment. Methods: Metabolic parameters were assessed in HepG2 and HEK293 cells using the newborn screening assay adapted for cell culture approaches, quantifying the levels of amino acids and acylcarnitines with mass spectrometry. Results: We were able to identify apoptosis-specific changes in the metabolite profile. Moreover, the amino acids alanine and glutamate were both significantly up-regulated in apoptotic HepG2 and HEK293 cells irrespective of the apoptosis inducer. Conclusion: Our observations clearly indicate the potential of metabolomics in detecting metabolic biomarkers applicable in theranostics and for monitoring drug efficacy.

AB - Background: Metabolomics is a versatile unbiased method to search for biomarkers of human disease. In particular, one approach in cancer therapy is to promote apoptosis in tumour cells; this could be improved with specific biomarkers of apoptosis for monitoring treatment. We recently observed specific metabolic patterns in apoptotic cell lines; however, in that study, apoptosis was only induced with one pro-apoptotic agent, staurosporine. Objective: The aim of this study was to find novel biomarkers of apoptosis by verifying our previous findings using two further pro-apoptotic agents, 5-fluorouracil and etoposide, that are commonly used in anticancer treatment. Methods: Metabolic parameters were assessed in HepG2 and HEK293 cells using the newborn screening assay adapted for cell culture approaches, quantifying the levels of amino acids and acylcarnitines with mass spectrometry. Results: We were able to identify apoptosis-specific changes in the metabolite profile. Moreover, the amino acids alanine and glutamate were both significantly up-regulated in apoptotic HepG2 and HEK293 cells irrespective of the apoptosis inducer. Conclusion: Our observations clearly indicate the potential of metabolomics in detecting metabolic biomarkers applicable in theranostics and for monitoring drug efficacy.

KW - Apoptosis

KW - Biomarkers

KW - Cancer

KW - Mass spectrometry

KW - Metabolomics

UR - http://www.scopus.com/inward/record.url?scp=84885698144&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84885698144&partnerID=8YFLogxK

U2 - 10.1111/joim.12117

DO - 10.1111/joim.12117

M3 - Review article

C2 - 24127940

AN - SCOPUS:84885698144

VL - 274

SP - 425

EP - 439

JO - Journal of Internal Medicine

JF - Journal of Internal Medicine

SN - 0954-6820

IS - 5

ER -